<DOC>
	<DOCNO>NCT00494884</DOCNO>
	<brief_summary>This study investigate efficacy safety vildagliptin patient low baseline level start HbA1C level 6.5 % support convenient early intervention combination therapy . In parallel , morning even dose evaluated patient population first time .</brief_summary>
	<brief_title>Vildagliptin 100 mg Once Daily v . Placebo add-on Therapy Patients With Type 2 Diabetes Inadequately Controlled With Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Male , nonfertile female female childbearing potential use medically approve birth control method Patients receive metformin least three month prior visit 1 stable dose minimum 8 week prior visit 1 Agreement maintain dose metformin throughout study Age range 1885 year inclusive . HbA1c range 6.5 8.0 % ( inclusive ) visit 1 Agreement maintain prior diet exercise habit full course study Ability comply study requirement sign informed consent participate study . Pregnant lactate female A history : type 1 diabetes , diabetes result pancreatic injury , secondary form diabetes , e.g . Cushing 's syndrome acromegaly . acute metabolic diabetic complication ketoacidosis hyperosmolar state ( coma ) within past 6 month . Any following significant laboratory abnormality : ALT , AST great 2 time upper limit normal range visit 1 . Direct bilirubin great upper limit normal range visit 1 . Serum creatinine level equal great 1.5 mg/dL ( 132 umol/L ) male , equal great 1.4 mg/dL ( 123 umol/L ) female , history abnormal creatinine clearance visit 1 . Clinically significant TSH value outside normal range visit 1 . Clinically significant laboratory abnormality , confirm repeat measurement , hyperglycemia , hyperinsulinemia , glycosuria visit 1 Treatment oral antidiabetic metformin within 3 month prior visit 1 Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>metformin combination</keyword>
</DOC>